EUVIMEDEUVIMED entdecken
Open Access

Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer

Zoulikha Rezoug, Stephanie P Totten, David Szlachtycz, Adrienne Atayan, Kristen Mohler, Sophie Albert, Leila Feng, Brianna Lemieux Anglin, Zhen Shen, Daniel Jimenez, Nancy Hamel, Nicholas Meti und 11 weitere

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.31427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Zoulikha Rezoug und 22 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Axis, Lady Davis Institute of the Jewish General Hospital, McGill University, Montréal, Québec, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Testing, Genetic Predisposition to Disease. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Between 5% and 10% of breast cancer cases are associated with an inherited germline pathogenic or likely pathogenic variant (GPV) in a breast cancer susceptibility gene (BCSG), which could alter local and systemic therapy recommendations. Traditional genetic testing criteria misses a proportion of these cases.

Objective

To evaluate the prevalence and clinicopathological associations of GPVs in 2 groups of BCSGs among an ethnically diverse cohort of women with newly diagnosed breast cancer. Design, Setting, and Participants This cross-sectional study, conducted at 3 Montreal hospitals between September 2019 and April 2022, offered universal genetic counseling and testing to all women with a first diagnosis of invasive breast cancer. Women were offered an obligatory primary panel of BRCA1 , BRCA2 , and PALB2 ( B1B2P2 ) and an optional secondary panel of 14 additional BCSGs. Eligible participants were women 18 years of age or older who received a diagnosis of a first primary invasive breast cancer not more than 6 months before the time of referral to the study. Data were analyzed from November 2023 to June 2024.

Results

Of 1017 referred patients, 805 were eligible and offered genetic counseling and testing, and 729 of those 805 (90.6%) consented to be tested. The median age at breast cancer diagnosis was 53 years (range, 23-91 years), and 65.4% were White and of European ancestry. Fifty-four GPVs were identified in 53 patients (7.3%), including 39 patients (5.3%) with B1B2P2 and 15 patients (2.1%) with 6 of the 14 secondary panel BCSGs ( ATM , BARD1 , BRIP1 , CHEK2 , RAD51D , and STK11 ). On multivariable analysis, clinical factors independently associated with B1B2P2 -positive status included being younger than 40 years of age at diagnosis (odds ratio [OR], 6.83; 95% CI, 2.22-20.90), triple-negative breast cancer (OR, 3.19; 95% CI, 1.20-8.43), high grade disease (OR, 1.68; 95% CI, 1.05-2.70), and family history of ovarian cancer (OR, 9.75; 95% CI, 2.65-35.85). Of 39 B1B2P2 -positive patients, 13 (33.3%) were eligible for poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors. Conclusions and Relevance In this cross-sectional universal genetic testing study of women with newly diagnosed invasive breast cancer, the prevalence of GPVs was 7.3%, with 5.3% of patients testing positive for B1B2P2 . Among B1B2P2 -women women, one-third were eligible for PARP inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsGenetic TestingGenetic Predisposition to DiseaseHumansFemaleMiddle AgedCross-Sectional StudiesAdultAgedFanconi Anemia Complementation Group N ProteinGenetic CounselingBRCA1 ProteinBRCA2 Protein

Substanzen

PALB2 protein, humanFanconi Anemia Complementation Group N ProteinBRCA1 protein, humanBRCA1 ProteinBRCA2 ProteinBRCA2 protein, human

Autor:innen und Institutionen

  • Cancer Axis, Lady Davis Institute of the Jewish General Hospital, McGill University, Montréal, Québec, Canada.
  • Cancer Research Program, Research Institute of the McGill University Health Centre, McGill University, Montréal, Québec, Canada.
  • Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
  • Optilab-McGill University Health Centre, Montreal, Quebec, Canada.
  • Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada.

Zitieren

APA

Rezoug, Z., Totten, S. P., Szlachtycz, D., Atayan, A., Mohler, K., Albert, S., Feng, L., Lemieux Anglin, B., Shen, Z., Jimenez, D., Hamel, N., Meti, N., Esfahani, K., Boileau, J. F., Prakash, I., Basik, M., Meterissian, S., Tremblay, F., Fleiszer, D., …, & Foulkes, W. D. (2024). Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.31427

Vancouver

Rezoug Z, Totten SP, Szlachtycz D, Atayan A, Mohler K, Albert S, et al. Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.31427

BibTeX
@article{Rezoug2024,
  author = {Rezoug, Zoulikha and Totten, Stephanie P and Szlachtycz, David and Atayan, Adrienne and Mohler, Kristen and Albert, Sophie and Feng, Leila and Lemieux Anglin, Brianna and Shen, Zhen and Jimenez, Daniel and Hamel, Nancy and Meti, Nicholas and Esfahani, Khashayar and Boileau, Jean-François and Prakash, Ipshita and Basik, Mark and Meterissian, Sarkis and Tremblay, Francine and Fleiszer, David and Anderson, Dawn and Chong, George and Wong, Stephanie M and Foulkes, William D},
  title = {Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.31427}
}
Kostenlos starten →